HSP90AB1 and acute myeloid leukemia: Furthermore, in AML and CML, HDAC inhibition leads to stronger binding of HSP90 to its inhibitor, 17-allylamino-17-demethoxygeldanamycin (17-AAG), fostering HSP90 degradation.